CVRx announces new real-world evidence demonstrating significant reductions in healthcare utilization with Barostim
MINNEAPOLIS, Feb. 12, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ('CVRx'), a commercial-stage medical device company, announced today the presentation of new real-world evidence at the Technology and Heart Failure Therapeutics (THT) conference in Boston. The study demonstrated large and statistically significant reductions in hospital visits (hospitalizations and emergency department visits) and length of stay after Barostim implantation, compared to before. The research was published simultaneously and is available now in the Journal of Cardiac Failure.
'Despite contemporary medications, the clinical and economic burden of heart failure remains unacceptably high. This new study showing significant reductions in real-world healthcare utilization associated with the Barostim implant is critically important for clinicians and payers when considering this device for their patients,' said Jacob Abraham, MD, Section Head of Advanced Heart Failure at Providence Heart Institute in Portland, Ore. 'While we know Barostim plus medications demonstrates long-term improvements in symptoms and quality of life, we now have compelling real-world evidence supporting a significant reduction in healthcare utilization as well.'
This analysis was performed using data from the Premier Healthcare Database, a large all-payer database including data from more than 1,300 institutions. Three hundred and six (306) Barostim patients were identified in the data set. Comparisons were performed for the 12 months prior to Barostim implant and for an average of almost two years post-implant (1.92±1.87 years). Length of stay was found to be significantly reduced. Hospital visits (hospitalizations and emergency department visits) were categorized as all-cause, cardiovascular, and heart failure related. The analysis found:
86% reduction in all-cause hospital visits (p<0.0001)
84% reduction in cardiovascular hospital visits (p<0.0001)
85% reduction in heart-failure hospital visits (p<0.0001)
'Congratulations to Dr. Jacob Abraham and co-authors for this important real-world analysis demonstrating remarkable reductions in healthcare utilization with Barostim,' said Dr. Philip Adamson, Chief Medical Officer of CVRx. 'We believe this study adds to the growing and consistent body of evidence supporting the clinical utility of Barostim. This is another example of our commitment to further develop and disseminate a strong pipeline of clinical and economic data supporting the many benefits of this therapy.'
About CVRx, Inc.CVRx is focused on the development and commercialization of the Barostim™ System, the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. Baroreceptors activate the body's baroreflex, which in turn triggers an autonomic response to the heart. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has also received the CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit www.cvrx.com.
Media Contact:Emily Meyers651.338.6204emeyers@cvrx.com
Investor Contact:Mark Klausner or Mike VallieICR Healthcare443.213.0501ir@cvrx.comSign in to access your portfolio
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 days ago
- Yahoo
Heart Failure Society of America and American Society for Preventive Cardiology Joint Statement Calls for a Shift in Heart Failure Prevention and Care
WASHINGTON, Aug. 13, 2025 /PRNewswire/ -- Heart failure affects more than 6 million Americans and is projected to reach over 11 million by 2050. Despite therapeutic advances, nearly 1 in 4 patients are readmitted within 30 days of discharge and 1 in 5 dies within a year. The economic burden exceeds $30 billion annually, representing a growing national health crisis, one that demands a new approach. For the first time, a joint scientific statement from the Heart Failure Society of America (HFSA) and the American Society for Preventive Cardiology (ASPC) places prevention at the forefront of heart failure care, marking a pivotal shift in how the field approaches the disease. Jointly published in the Journal of Cardiac Failure (JCF) and the American Journal of Preventive Cardiology, "The Continuum of Prevention and Heart Failure in Cardiovascular Medicine" provides an integrated framework of preventive strategies across all stages of heart failure, regardless of ejection fraction, from risk identification in healthy individuals to secondary prevention in those with established disease, and even tertiary strategies in patients with advanced therapies such as LVADs or heart transplants. The statement reframes heart failure as a preventable condition rather than an inevitable outcome, calling for clinicians to identify and manage risk factors earlier, even decades before symptoms arise. For patients, this means heart failure prevention begins not in the hospital, but at routine health visits, through strategies like blood pressure control, glucose management, weight loss, genetic risk screening, and lifestyle interventions. This is the first national roadmap to formally link preventive cardiology with heart failure management, emphasizing a collaborative, multidisciplinary model. "This is a wake-up call for the field," said Martha Gulati, MD, MS, co-lead author. "We need to break down silos between preventive cardiology and heart failure care and create seamless strategies to identify and manage risk earlier. This needs to be a part of cardiovascular disease prevention." "Prevention in heart failure isn't a phase—it's a mindset. It applies not only before the onset of disease but continues after diagnosis and even following heart replacement therapy. At every stage, prevention ensures we care for the whole person, not just the failing heart," added Anuradha Lala, MD, co-chair. "This joint statement equips clinicians with a roadmap for early intervention, team-based care, and emerging tools to improve outcomes." Key Highlights from the Statement: Expanded Focus on Risk Factors: Emphasizes both traditional risks, such as hypertension, diabetes, and obesity, and emerging drivers including sex-specific (e.g., hypertensive disorders of pregnancy, premature menopause), genetic, environmental, and social determinants of health. Lifespan-Based Prevention Framework: Advocates for prevention strategies across all stages of heart failure, from at-risk individuals to those with advanced therapies. Use of Innovative Tools: Supports incorporation of biomarkers, polygenic risk scores, and AI-based models to improve early detection and risk stratification. Team-Based Care Models: Promotes multidisciplinary collaboration across specialties to deliver coordinated, preventive cardiovascular care. Holistic Approach to Prevention: Stresses the role of lifestyle, nutrition, cardiac rehab, psychological health, and equity-driven care in improving outcomes. The statement urges institutions and clinicians to adopt a prevention-first mindset to curb the growing burden of heart failure. The Continuum of Prevention and Heart Failure in Cardiovascular Medicine: A Joint Statement from the Heart Failure Society of America and the American Society for Preventive Cardiology is available online in the JCF at In addition to reviewing the guidance found within The Continuum of Prevention and Heart Failure in Cardiovascular Medicine: A Joint Statement from the Heart Failure Society of America and the American Society for Preventive Cardiology, clinicians can use the Top Take-Home Messages slide deck, designed by the statement's lead author, as a quick reference guide, available on the website. View all HFSA published scientific statements, guidelines and other clinical documents. About the Heart Failure Society of America The Heart Failure Society of America, Inc. (HFSA) represents the first organized effort by heart failure experts from the Americas to provide a forum for all those interested in heart function, heart failure, and congestive heart failure (CHF) research and patient care. The mission of HFSA is to provide a platform to improve and expand heart failure care through collaboration, education, innovation, research, and advocacy. HFSA members include physicians, scientists, nurses, nurse practitioners, pharmacists, trainees, other healthcare workers and patients. For more information, visit About the Journal of Cardiac Failure The Journal of Cardiac Failure (JCF) publishes the highest quality science in the field of heart failure with a focus on diversity, equity, and inclusion, mentorship, multidisciplinary partnerships, and patient-centeredness. Published papers span original investigator-initiated work to state-of-the-art reviews, guidelines and scientific statements, expert perspectives, early career and trainee spotlight pieces, patient and patient-partner narratives. JCF also emphasizes the power of language and prioritizes innovative approaches to dissemination of published work to reach and impact the broader heart failure community. About the American Society for Preventive Cardiology When the ASPC was founded in 1985, its members were academic physicians and educators, including frequent recipients of the National Heart, Lung, and Blood Institute (NHLBI) Preventive Cardiology Academic Award (PCAA). The organization's goals were to develop programs that enhanced basic and clinical education, and to initiate and expand interdisciplinary clinical services and research initiatives in preventive cardiology. In 2009, the goals of the organization became broader. Membership has grown to more than 1,400 academic and clinical practitioners as the ASPC seeks to represent the increasingly multidisciplinary group of health care providers (including physicians, nurses, nurse practitioners, dieticians, and other allied health care specialists) along with researchers who share an interest in and passion for preventive cardiology. The mission of the American Society for Preventive Cardiology is to provide a framework for the educational interests of health care providers to promote the primary and secondary prevention of cardiovascular disease. The specific goals of the organization are to organize and conduct professional educational programs to emphasize the processes of risk factor identification and intervention based on the most rigorous basic, clinical, and population science. Objectives to achieve these goals include stand-alone CME/CE and non-CME/CE programs on CVD prevention, and partnerships with other professional groups to present and promote CME/CE and non-CME/CE programs on CVD prevention and to enhance opportunities for preventive cardiology at all levels of professional development. Media Contact: Laura Poko, 301-798-4493, ext. 226, lpoko@ View original content to download multimedia: SOURCE Heart Failure Society of America
Yahoo
29-07-2025
- Yahoo
CVRx to Present at the Canaccord Genuity 45th Annual Growth Conference
MINNEAPOLIS, July 29, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today announced that the management team will present at the Canaccord Genuity 45th Annual Growth Conference on Tuesday, August 12, 2025. The Company is scheduled to present at 3:00pm Eastern Time the same day via webcast. A live audio webcast of the conference presentation will be available online at the investor relations page of the Company's website at About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit Investor Contact: Mark Klausner or Mike Vallie ICR Westwicke 443-213-0501 ir@ Media Contact: Emily Meyers CVRx, Inc. 763-416-2853 emeyers@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
16-07-2025
- Yahoo
CVRx Announces Positive News on Outpatient Payment for Barostim
MINNEAPOLIS, July 16, 2025 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ('CVRx'), a commercial-stage medical device company, announced today that the Centers for Medicare and Medicaid Services (CMS) has proposed to keep the Barostim implant procedure as part of the New Technology Ambulatory Payment Classification (APC) 1580, with an associated payment of approximately $45,000 for procedures performed in the outpatient setting. CMS is also soliciting comments about the need for a Level 6 Neurostimulator APC. We expect CMS will publish the 2026 Medicare Hospital Outpatient Prospective Payment System (OPPS) final rule in November, which is expected to take effect on January 1, 2026. This proposal follows two other positive developments in the last nine months relating to reimbursement rates. As of Oct. 1, 2024, Barostim was assigned to a higher paying MS-DRG for inpatient procedures. In that same month it was announced that Barostim will transition from Category III to Category I CPT codes for physician payments as of Jan. 1, 2026. These reimbursement updates underscore the clinical value of Barostim and reinforce its role in the heart failure care continuum. 'We appreciate CMS' proposal to keep Barostim in APC 1580, ensuring appropriate payment for the Barostim implant procedure,' said Kevin Hykes, President and CEO of CVRx. 'These reimbursement updates, along with the favorable proposed payment levels included in the recently released physician fee schedule, allow us to continue our progress toward expanding access to Barostim for patients suffering from heart failure with reduced ejection fraction, which we believe will help support its broader market adoption and long-term growth.' About CVRx, Inc. CVRx is a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases. Barostim™ is the first medical technology approved by FDA that uses neuromodulation to improve the symptoms of patients with heart failure. Barostim is an implantable device that delivers electrical pulses to baroreceptors located in the wall of the carotid artery. The therapy is designed to restore balance to the autonomic nervous system and thereby reduce the symptoms of heart failure. Barostim received the FDA Breakthrough Device designation and is FDA-approved for use in heart failure patients in the U.S. It has been certified as compliant with the EU Medical Device Regulation (MDR) and holds CE Mark approval for heart failure and resistant hypertension in the European Economic Area. To learn more about Barostim, visit Forward Looking Statement This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements about the proposal to maintain the APC for the Barostim implant procedure and progress toward expanded access to Barostim are forward-looking statements. These statements speak only as of the date of this press release and are based on our current expectations and projections about future events, and are subject to a number of known and unknown risks and uncertainties that could cause actual results to differ from our expectations, including the final OPPS rule, which could differ from the proposed rule, following the public comment period, and the actual impact of the APC on actual reimbursement and patient access. These forward-looking statements speak only as of the date of this press release. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise. Media Contact:Emily MeyersCVRx, Inc.763-416-2853emeyers@ Investor Contact:Mark Klausner or Mike VallieICR Healthcare443-213-0501ir@ in to access your portfolio